Medicare beneficiaries who rely on Ozempic or Wegovy will pay sharply less starting in 2027 after the federal government locked in a negotiated price of $274 per month for both drugs, a reduction of roughly 71 percent from current costs. The price cut, secured through the Inflation Reduction Act’s second cycle of Medicare drug price negotiations, applies to three Novo Nordisk products: Ozempic, Rybelsus, and Wegovy. A separate White House initiative sets an even lower figure of $245 per month under a most-favored-nation pricing framework, creating two overlapping price ceilings that have yet to be reconciled.
Two price ceilings collide over Ozempic and Wegovy in 2027
The $274 monthly “maximum fair price” was established through the Inflation Reduction Act’s Medicare Drug Price Negotiation Program, which designated these drugs for its second negotiation cycle, known as IPAY 2027. Novo Nordisk Inc. signed participation agreements for Ozempic, Rybelsus, and Wegovy, according to the Centers for Medicare & Medicaid Services (CMS), clearing the way for the negotiated rates to take effect. Participation means the manufacturer accepts the statutory framework for negotiation and agrees that Medicare will pay no more than the negotiated ceiling price when the new policy year begins.
At the same time, the administration has pointed to a separate executive order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,” which directs federal agencies to explore tying Medicare payments to prices paid in lower-cost countries. A White House fact sheet under that order lists a $245 most-favored-nation price for the same Novo Nordisk drugs, implying an even steeper discount than the IRA negotiation produced.
The gap between $274 and $245 per month is not just an accounting detail. If the administration ultimately treats the lower MFN figure as the binding ceiling for 2027 claims, CMS would need to adjust the IRA maximum fair prices downward before the calendar year begins. That would effectively force Novo Nordisk to accept terms below what it already negotiated, a move that could prompt legal challenges or demands to reopen talks. For the roughly 3.4 million Medicare Part D enrollees who filled GLP‑1 prescriptions in recent years, the practical question is which number will appear on their pharmacy receipts once both policies are in play.
What CMS documents and White House orders actually say
CMS has laid out the negotiated prices in a public dataset on its selected drugs page, where Ozempic, Rybelsus, and Wegovy are each listed with a $274 monthly maximum fair price. Those figures are the product of a statutory process created by the Inflation Reduction Act, which authorizes the Health and Human Services secretary to identify high-spend drugs and bargain down what Medicare pays.
To implement that authority, HHS released detailed guidance for the second negotiation cycle, confirming that prices agreed to during this round will take effect in 2027. In a department press release, officials describe the cycle as a “historic” expansion of Medicare’s ability to secure lower prices and specify that the negotiated amounts will apply across both stand-alone Part D plans and Medicare Advantage plans with drug coverage. The same guidance underscores that manufacturers participating in the program are subject to excise taxes or civil penalties if they refuse to honor the final negotiated prices.
That formal CMS and HHS record sits uneasily alongside the White House’s most-favored-nation language. The MFN framework, as summarized in the White House fact sheet, directs agencies to pursue international reference pricing but does not spell out how those targets interact with IRA-negotiated maximum fair prices already on the books. In other words, CMS has clear, dataset-backed numbers for 2027, while the MFN initiative sets a policy aspiration that could require additional rulemaking or legislation to fully enforce.
One source conflict is worth flagging directly. On the one hand, CMS’s published materials, including the negotiated prices dataset and the final guidance press release, treat $274 as the operative ceiling for Ozempic, Rybelsus, and Wegovy in 2027. On the other hand, the White House’s MFN fact sheet highlights a $245 benchmark that, if implemented as a hard cap, would supersede the IRA figures and reopen the question of what Medicare actually pays. Until the administration issues clarifying regulations or Congress amends the underlying statutes, both numbers will coexist in the policy debate.
For beneficiaries, the uncertainty is largely about the size of the savings rather than their existence. Whether the final ceiling is $274 or $245, average out-of-pocket costs for these GLP‑1 drugs will fall dramatically compared with today’s list prices, especially once plan formularies and low‑income subsidies are layered on top of the new federal caps. For drugmakers and insurers, however, the unresolved tension between IRA negotiations and MFN ambitions will shape revenue forecasts, coverage decisions, and the broader politics of high-cost weight-loss and diabetes treatments for years to come.
